Sagimet Biosciences (STU:0O2) EBIT : €-50.51 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sagimet Biosciences EBIT?

Sagimet Biosciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was €-17.38 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was €-50.51 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sagimet Biosciences's annualized ROC % for the quarter that ended in Dec. 2024 was -585.59%. Sagimet Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -16,687.64%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sagimet Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 300.60%.

Sagimet Biosciences EBIT Historical Data

The historical data trend for Sagimet Biosciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sagimet Biosciences EBIT Chart

Sagimet Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT

Get a 7-Day Free Trial

-9.35

-20.99

-29.32

-28.19

-52.00

Sagimet Biosciences Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT	Get a 7-Day Free Trial												-8.68	-8.07	-9.84	-15.23	-17.38

Competitive Comparison of Sagimet Biosciences's EBIT

For the Biotechnology subindustry, Sagimet Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sagimet Biosciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's EV-to-EBIT falls into.

Sagimet Biosciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-50.51 Mil.

Sagimet Biosciences (STU:0O2) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sagimet Biosciences's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

	ROC % (Q: Dec. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2024 )	+	Invested Capital (Q: Dec. 2024 ))	/ count )
=	-69.504 * ( 1 - 0% )	/	( (16.51	+	7.228)	/ 2 )
=	-69.504	/	11.869
=	-585.59 %

where

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	157.472	-	3.572	-	( 137.39	-	max(0, 3.687	-	141.628	+	137.39	))
=	16.51

	Invested Capital		(Q: Dec. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	153.047	-	4.174	-	( 144.444	-	max(0, 4.254	-	145.899	+	144.444	))
=	7.228

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Sagimet Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2024		Q: Dec. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-69.504	/	( ( (0.103 + max(0.656, 0))	+	(0.074 + max(-2.725, 0)) )	/	2 )
=	-69.504	/	( ( 0.759	+	0.074 )	/	2 )
=	-69.504	/	0.4165
=	-16,687.64 %

where Working Capital is:

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	4.238)	-	(3.572	+	0	+	0.0099999999999998)
=	0.656

	Working Capital		(Q: Dec. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.455)	-	(4.174	+	0	+	0.0059999999999993)
=	-2.725

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sagimet Biosciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2024 )
	=	-50.509	/	-16.803
	=	300.60 %

Sagimet Biosciences EBIT Related Terms

Thank you for viewing the detailed overview of Sagimet Biosciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sagimet Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sagimet Biosciences Inc (STU:0O2) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

SGMT:USA 0O2:Germany

Address

155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402

Website

https://www.sagimet.com

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Sagimet Biosciences Headlines

No Headlines